Medpace Holdings Inc vs ServiceNow Inc — how do they compare? Medpace Holdings Inc trades at $615.1 (market cap $16.82B), while ServiceNow Inc trades at $140.75 (market cap $144.48B). The key difference: ServiceNow Inc is far larger — about 8.6× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ServiceNow Inc for 54 Days on average.
| MEDP | NOW | |
|---|---|---|
Market Cap | $16.82B | $144.48B |
Volume | 223,093 | 11,801,699 |
Sector | Health | Technology |
52-Week High | $630.19 | $189.26 |
52-Week Low | $393.42 | $83.00 |
Typical Hold Time | 14 Days | 54 Days |
Enterprise Value | $16.44B | $148.27B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
ServiceNow (NOW) trades at $137.87, down slightly by 0.07% on the day. The stock shows strong fundamental momentum with revenue growing from $7.2B in 2022 to $13.3B in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish with the price above key moving averages, while analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $146.04 consensus target. The company's AI business has surpassed $1 billion in annual contract value, driving investor optimism.
ServiceNow presents a compelling growth story with robust AI adoption and expanding enterprise workflow solutions. The primary investment opportunity lies in the company's leadership position in enterprise AI and strong subscription revenue growth. Key risks include premium valuation multiples (P/E of 87.34), increasing competition in cloud software, and potential margin pressure as AI investments scale. The stock offers upside to analyst targets but requires monitoring of execution against ambitious growth projections.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →